Owen Carolyn, Barnett Michael, Fitzgibbon Jude
Centre for Medical Oncology, Barts & the London School of Medicine & Dentistry, London, UK.
Br J Haematol. 2008 Jan;140(2):123-32. doi: 10.1111/j.1365-2141.2007.06909.x.
Familial occurrence of myelodysplasia (MDS) and/or acute myeloid leukaemia (AML) is rare but can provide a useful resource for the investigation of predisposing mutations in these myeloid malignancies. To date, examination of families with MDS/AML has lead to the detection of two culprit genes, RUNX1 and CEBPA. Germline mutations in RUNX1 result in familial platelet disorder with propensity to myeloid malignancy and inherited mutations of CEBPA predispose to AML. Unfortunately, the genetic cause remains obscure in most other reported pedigrees. Further insight into the molecular mechanisms of familial MDS/AML will require awareness by clinicians of new patients with relevant family histories.
骨髓增生异常综合征(MDS)和/或急性髓系白血病(AML)的家族性发病较为罕见,但可为研究这些髓系恶性肿瘤的易感突变提供有用资源。迄今为止,对患有MDS/AML的家族进行检测已发现两个致病基因,即RUNX1和CEBPA。RUNX1的种系突变会导致家族性血小板疾病并易患髓系恶性肿瘤,而CEBPA的遗传性突变易引发AML。不幸的是,在其他大多数已报道的家系中,遗传原因仍不清楚。要进一步深入了解家族性MDS/AML的分子机制,临床医生需要留意有相关家族病史的新患者。